• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

7.360 +0.230 (+3.23%)
Official Closing Price Updated: 4:15 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 767,198
Open 7.110
Bid (Size) 6.800 (200)
Ask (Size) 8.300 (300)
Prev. Close 7.130
Today's Range 7.000 - 7.410
52wk Range 3.730 - 15.74
Shares Outstanding 61,758,994
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Fulcrum (FULC) Q1 2026 Earnings Transcript ↗
April 27, 2026
Fulcrum (FULC) Q1 2026 Earnings Transcript 
Via The Motley Fool
Fulcrum Therapeutics (NASDAQ:FULC) Beats Q1 Estimates as Pociredir Data Fuels Optimism ↗
April 27, 2026
Via Chartmill

Performance

YTD
-32.6%
-32.6%
1 Month
-1.6%
-1.6%
3 Month
-31.4%
-31.4%
6 Month
-15.9%
-15.9%
1 Year
+68.0%
+68.0%

More News

Read More
News headline image
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
April 27, 2026
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
April 27, 2026
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics (NASDAQ:FULC) Q4 2025 Earnings: Pociredir Data Steals Spotlight Amid In-Line Financials ↗
February 24, 2026
Via Chartmill
News headline image
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
April 20, 2026
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
March 26, 2026
Via MarketMinute
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
March 26, 2026
Via MarketMinute
News headline image
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
March 19, 2026
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
March 03, 2026
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
February 24, 2026
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
February 24, 2026
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
February 17, 2026
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2026
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active
December 09, 2025
Via AB Newswire
News headline image
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
December 08, 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
What's going on in today's session ↗
December 08, 2025
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
December 08, 2025
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
December 08, 2025
Via Chartmill
News headline image
Fulcrum Stock Nears March 2024 Highs: Early Stage Sickle-Cell Data Sparks Target Price Hikes ↗
December 08, 2025
Via Stocktwits
News headline image
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Fulcrum Therapeutics, Inc. - Common Stock publicly traded?
Yes, Fulcrum Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Fulcrum Therapeutics, Inc. - Common Stock trade on?
Fulcrum Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock?
The ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock is FULC on the Nasdaq Stock Market
What is the current price of Fulcrum Therapeutics, Inc. - Common Stock?
The current price of Fulcrum Therapeutics, Inc. - Common Stock is 7.360
When was Fulcrum Therapeutics, Inc. - Common Stock last traded?
The last trade of Fulcrum Therapeutics, Inc. - Common Stock was at 05/01/26 04:15 PM ET
What is the market capitalization of Fulcrum Therapeutics, Inc. - Common Stock?
The market capitalization of Fulcrum Therapeutics, Inc. - Common Stock is 454.55M
How many shares of Fulcrum Therapeutics, Inc. - Common Stock are outstanding?
Fulcrum Therapeutics, Inc. - Common Stock has 455M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap